Hisamitsu Pharmaceutical Co., Inc. (4530.T)
- Previous Close
3,710.00 - Open
3,740.00 - Bid --
- Ask --
- Day's Range
3,688.00 - 3,779.00 - 52 Week Range
3,541.00 - 5,497.00 - Volume
224,600 - Avg. Volume
168,531 - Market Cap (intraday)
286.233B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
20.49 - EPS (TTM)
184.42 - Earnings Date Jul 11, 2024 - Jul 15, 2024
- Forward Dividend & Yield 86.00 (2.28%)
- Ex-Dividend Date Aug 29, 2024
- 1y Target Est
3,950.00
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to approximately 40 countries and regions, including Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
www.hisamitsu.co.jp--
Full Time Employees
February 29
Fiscal Year Ends
Sector
Related News
Performance Overview: 4530.T
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4530.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4530.T
Valuation Measures
Market Cap
286.23B
Enterprise Value
163.01B
Trailing P/E
20.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.02
Price/Book (mrq)
1.08
Enterprise Value/Revenue
1.15
Enterprise Value/EBITDA
6.69
Financial Highlights
Profitability and Income Statement
Profit Margin
9.86%
Return on Assets (ttm)
2.56%
Return on Equity (ttm)
5.49%
Revenue (ttm)
141.71B
Net Income Avi to Common (ttm)
13.97B
Diluted EPS (ttm)
184.42
Balance Sheet and Cash Flow
Total Cash (mrq)
125.32B
Total Debt/Equity (mrq)
0.79%
Levered Free Cash Flow (ttm)
-2.7B
Research Analysis: 4530.T
Company Insights: 4530.T
4530.T does not have Company Insights